These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1538 related items for PubMed ID: 16919893

  • 21. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ, Thiele J.
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [Abstract] [Full Text] [Related]

  • 22. Polycythemia vera: scientific advances and current practice.
    Tefferi A, Spivak JL.
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [Abstract] [Full Text] [Related]

  • 23. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J, Kvasnicka HM, Zankovich R, Diehl V.
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [Abstract] [Full Text] [Related]

  • 24. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
    Thiele J, Kvasnicka HM, Orazi A.
    Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
    [Abstract] [Full Text] [Related]

  • 25. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 26. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P, Hanrahan V, Baker B, Romeril K.
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [Abstract] [Full Text] [Related]

  • 27. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A, Alvarez-Larrán A, Morales-Indiano C, García-Pallarols F, Martínez-Avilés L, Angona A, Senín A, Bellosillo B, Besses C.
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [Abstract] [Full Text] [Related]

  • 28. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 29. Prodromal myeloproliferative neoplasms: the 2008 WHO classification.
    Kvasnicka HM, Thiele J.
    Am J Hematol; 2010 Jan; 85(1):62-9. PubMed ID: 19844986
    [Abstract] [Full Text] [Related]

  • 30. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 31. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 32. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K.
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [Abstract] [Full Text] [Related]

  • 33. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond.
    Michiels JJ.
    Hematology; 2005 Jan; 10 Suppl 1():215-23. PubMed ID: 16188676
    [Abstract] [Full Text] [Related]

  • 34. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T, Adachi S, Morimoto A.
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [Abstract] [Full Text] [Related]

  • 35. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW.
    Cancer Res; 2006 Dec 01; 66(23):11156-65. PubMed ID: 17145859
    [Abstract] [Full Text] [Related]

  • 36. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 37. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J.
    Neth J Med; 1999 Feb 12; 54(2):46-62. PubMed ID: 10079679
    [Abstract] [Full Text] [Related]

  • 38. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
    Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, Pahl HL.
    Ann Hematol; 2004 Jun 12; 83(6):364-70. PubMed ID: 15034760
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 77.